RadNet, Inc. (RDNT) is a Healthcare stock trading at $76.89 (as of 2026-08-25), with a market capitalization of $6.05B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
RadNet, Inc. provides outpatient diagnostic imaging services in the United States, offering modalities such as MRI, CT, PET, nuclear medicine, mammography, ultrasound, and related radiology procedures. It also develops and supplies imaging-industry computer systems and provides AI solutions, including support for mammography and applications in lung and prostate cancer.
Understand RadNet, Inc.: how it makes money
RadNet runs 435 outpatient imaging centers in the US, performing MRI, CT, PET, mammography, and other scans and billing insurers and referring physicians for each procedure. About 29% of procedural volume is now advanced imaging (MRI, CT, PET), and a smaller Digital Health and AI software business is growing on top of that base.
The margin engine is the shift of scan volume from routine X-ray toward advanced modalities (MRI, CT, PET), which reimburse at a multiple of per-procedure rates; the Digital Health and AI software layer then adds low-capex recurring revenue on top of the imaging-center base.
Business quality (Mixed): High revenue growth (25% YoY) but thin 6% operating margin and negative ROE mean the business is still working to convert volume into profit, while site-neutrality regulation is a live policy overhang.
Bull case
Revenue compounding at mid-20s: Quarterly revenue hit $600M, up 25% year over year, as management points to sustained patient demand, new capacity investments, and advanced-modality volume growth driving the core imaging business upward.
Digital Health building a second engine: The Digital Health segment contributed $30M in quarterly revenue (5% of total) and management described a rapidly expanding funnel with substantial contracted opportunity. That AI and PACS software layer is a low-capex, recurring-revenue complement to the capital-intensive imaging-center model.
Balance sheet funds the flywheel: Management highlighted that current liquidity supports continued acquisitions, organic capacity expansion, and new health-system partnerships, which are the channels through which RadNet adds imaging volume without building every center from the ground up.
Bear case
Labor inflation squeezing a thin margin: Operating margin sits at 6%, and management flagged that technologist and radiologist salary inflation is actively pressuring it. Because imaging is a multi-shift, labor-intensive operation, even small wage increases flow through disproportionately and cap how much volume growth converts to profit.
Site-neutrality rules could cut reimbursement: Proposed site-neutrality rules could materially reduce the outpatient reimbursement RadNet collects per scan, which would directly erode the per-procedure revenue the 25% growth narrative depends on and compress an already thin 6% operating margin.
Backlogs threaten referral relationships: Management acknowledged that capacity constraints and scan backlogs risk losing customers and referring physicians. In a referral-driven imaging business, even a modest loss of a key referring source or health-system partner would cap the volume growth the model needs to reach a steadier-margin profile.